A majority of drug makers and payers cited the Medicaid best price rule as an obstacle to entering outcomes-based pay arrangements, which are considered a tool for curbing drug costs, in a survey published Wednesday (Feb. 13). That message has gotten through to Congress. Two senators are writing bipartisan legislation that would make it easier to use outcomes-based contracts. Sens. Bill Cassidy (R-LA) and Mark Warner (D-VA) are seeking feedback on a bill to exempt outcomes-based contracts from the Medicaid...